Biotech startup moves US headquarters to Dallas for AI-powered IVF expansion

Overture Life, a Madrid-based biotechnology company, is relocating its U.S. headquarters from San Antonio to East Dallas, where it will establish a 4,500-square-foot AI-powered IVF robotics hub in the Bogart Building. The move positions the company to tap into Dallas’s growing biotech talent pool of 27,000 professionals across 850 companies while expanding access to automated fertility treatments in a market where the U.S. significantly lags behind Europe in IVF capacity.

Why it matters: Overture Life combines artificial intelligence and robotics to automate critical IVF processes, addressing major capacity constraints in American fertility care.

• The U.S. performs only about 900 IVF cycles per million women compared to Europe’s average of over 3,000 cycles per million women.
• The Dallas facility will focus on non-invasive embryo assessment testing, analyzing fluid surrounding stored embryos to guide fertility physicians without requiring invasive biopsies.
• By January’s end, the Google Ventures-backed company will make a multi-million-dollar investment to convert the office space into a fully equipped laboratory.

The technology advantage: Overture’s automated systems deliver measurable improvements in both outcomes and efficiency across multiple IVF processes.

• Their DaVitri automated egg-freezing system achieves a 12 percent improvement in egg survival rates while increasing clinic capacity by 300 percent without additional staff.
• The ICSI.A robotic sperm injection system helped deliver the world’s first babies born from robotic sperm injection in 2024, standardizing a process that typically varies widely between labs and professionals.

Why Dallas matters: CEO Hans Gangeskar, a lawyer and software engineer based in Virginia, chose Dallas for strategic operational advantages beyond just talent acquisition.

• “The most important thing for this facility is lab talent that knows how to run these machines in a lab facility and a local regulatory climate where inspectors will come quickly when you need them to inspect something,” Gangeskar explained.
• Dallas offers direct flights to all of Overture’s other operational hubs in Virginia, Palo Alto, and Madrid, facilitating seamless coordination across the company’s global operations.

Current operations: Overture’s IVF platforms are already operational across multiple international markets while pursuing full FDA approval for U.S. expansion.

• The company currently operates in clinics across Brazil, Argentina, Chile, Bolivia, Panama, Turkey, and New Jersey.
• They’re actively collaborating with clinics throughout Texas and nationwide to advance regulatory approval of their automated platforms.

The bigger picture: The Dallas expansion reflects a broader trend of converting traditional office spaces into specialized laboratory facilities across North Texas.

• This mirrors developments like the renovation of the former EDS headquarters in Plano as part of the Texas Research Quarter development from NexPoint, a Dallas-based investment firm.
• “The infrastructure we’re establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States,” said Hafsa Irfan, Overture Life’s head of clinical operations for the Dallas facility.

What they’re saying: Gangeskar emphasized the urgent need to address accessibility barriers in fertility care.

• “You don’t need to talk to a lot of people to realize that it’s hard to get into an IVF clinic. There’s a waiting list, and it’s very expensive,” he noted.
• “We need to build a lot of new clinics and increase capacity in those clinics.”